Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Fowler

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
JTO Clinical and Research Reports|July 31, 2023
B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung AdenocarcinomaIbiayi Dagogo-Jack, Ivan Valiev, Nikita Kotlov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN StudyBruce D Cheson, Neil Chua, Jiri Mayer, et al.
The Lancet. Oncology|June 28, 2016
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialLaurie H Sehn, Neil Chua, Jiri Mayer, et al.
Hemasphere|November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaSteven E Coutre, Ian W Flinn, Sven de Vos, et al.
British Journal of Haematology|April 7, 2017
Characteristics, management, and outcomes of patients with follicular dendritic cell sarcomaPreetesh Jain, Sarah A Milgrom, Keyur P Patel, et al.
Cell Reports. Medicine|August 20, 2025
AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinomaDanil Stupichev, Natalia Miheecheva, Ekaterina Postovalova, et al.
Leukemia & Lymphoma|August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphomaBei Hu, Anas Younes, Jason R Westin, et al.
Cell Reports|August 17, 2022
Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneityNatalia Miheecheva, Ekaterina Postovalova, Yang Lyu, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Radiation Oncology (London, England)|September 27, 2015
Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphomaBassem Youssef, JoAnn Shank, Jay P Reddy, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
JTO Clinical and Research Reports|July 31, 2023
B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung AdenocarcinomaIbiayi Dagogo-Jack, Ivan Valiev, Nikita Kotlov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN StudyBruce D Cheson, Neil Chua, Jiri Mayer, et al.
The Lancet. Oncology|June 28, 2016
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialLaurie H Sehn, Neil Chua, Jiri Mayer, et al.
Hemasphere|November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaSteven E Coutre, Ian W Flinn, Sven de Vos, et al.
British Journal of Haematology|April 7, 2017
Characteristics, management, and outcomes of patients with follicular dendritic cell sarcomaPreetesh Jain, Sarah A Milgrom, Keyur P Patel, et al.
Cell Reports. Medicine|August 20, 2025
AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinomaDanil Stupichev, Natalia Miheecheva, Ekaterina Postovalova, et al.
Leukemia & Lymphoma|August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphomaBei Hu, Anas Younes, Jason R Westin, et al.
Cell Reports|August 17, 2022
Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneityNatalia Miheecheva, Ekaterina Postovalova, Yang Lyu, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Radiation Oncology (London, England)|September 27, 2015
Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphomaBassem Youssef, JoAnn Shank, Jay P Reddy, et al.
Pageof 9